ASCO 2025 showcased breakthroughs in sarcoma treatment, emphasizing precision medicine, immunotherapy, and promising new ...

CAMBRIDGE, MA, USA I July 21, 2025 I Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on ...

AstraZeneca (AZ) has shared positive overall survival (OS) results from a late-stage study of its epidermal growth factor ...

DelveInsight’s, “Multiple Sclerosis Pipeline Insight 2025” report provides comprehensive insights about 75+ companies and 80+ ...

Targeting SHP2 has emerged as a promising approach for treating cancers driven by receptor tyrosine kinases. Although allosteric SHP2 inhibitors have shown strong antitumor activity in preclinical ...

DelveInsight's, “Gastrointestinal Stromal Tumors Pipeline Insight 2025” report provides comprehensive insights about 25+ ...

Exelixis EXEL has put up a stellar performance so far this year. Shares of the biotech company have rallied 35.2% in the past three months compared with the industry’s growth of 11.8%. The stock has ...

Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective non-hormonal contraception during treatment with AUGTYRO and for 2 months following ...

Receptor tyrosine kinases (RTKs) are key regulators of cellular signaling and are frequently involved in cancer development. As their activation depends on ATP binding to the kinase domain, precisely ...

Nuvalent Inc. has identified proto-oncogene tyrosine-protein kinase ROS (ROS1; MCF3) and/or ALK tyrosine kinase receptor inhibitors reported to be useful for the treatment of cancer.

It increases binding to Fc receptors on immune cells to enhance immune engagement and thus leads to improved anti-tumor activity, especially in patients with CD16A polymorphisms of FcγRIIIa. Tukysa ...